Endocrine therapy is the main therapeutic option for patients with estrogen receptor (ERa)-positive breast cancer. Resistance to this treatment is often associated with estrogen-independent activation of ERa. In this study, we show that in ERa-positive breast cancer cells, activation of the receptor tyrosine kinase RET (REarranged during Transfection) by its ligand GDNF results in increased ERa phosphorylation on Ser118 and Ser167 and estrogen-independent activation of ERa transcriptional activity. Further, we identify mTOR as a key component in this downstream signaling pathway. In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug. In tamoxifen-resistant (TAM R -1) MCF7 cells, targeting RET restored tamoxifen sensitivity. Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERa-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors. Together these findings identify RET as a potentially important therapeutic target in ERa-positive breast cancers and in particular in tamoxifen-resistant tumors.
Introduction
The majority of breast tumors (70%) at primary diagnosis are estrogen receptor-a (ERa) positive (Dowsett et al., 2006) . The estrogen-ERa complex binds to estrogen response elements on the promoter of target genes, and together with pioneering transcription factors, histone acetyl transferases and other coactivators regulates the transcription of estrogen-dependent genes controlling proliferation and cell survival (Ali and Coombes, 2000; Green and Carroll, 2007) . The knowledge that estrogen has a pivotal role in breast cancer has been exploited clinically by the development of endocrine therapies. These seek to deprive the hormone-dependent tumor cells of estrogens using aromatase inhibitors, which block the conversion of androgens into estrogens, or the use of anti-estrogens such as tamoxifen or fulvestrant (ICI182780), both of which compete with estrogen for receptor binding (Ali and Coombes, 2002; Howell and Dowsett, 2004) . Unfortunately, the beneficial actions of existing endocrine treatments are attenuated by the ability of tumors to circumvent the need for steroid hormones, while in most cases, retaining functional nuclear steroid receptors (Nicholson et al., 1999; Ali and Coombes, 2002; Arpino et al., 2008) .
Endocrine resistance has been strongly associated with cross-talk between upstream kinases and ERa, resulting in estrogen-independent activation of the ERa or hyper-sensitization to residual estrogen (Ali and Coombes, 2002; Massarweh and Schiff, 2006; Musgrove and Sutherland, 2009 ). In particular, phosphorylation of Ser118 and Ser167 in the AF1 domain of ERa drive estrogen-independent transcriptional activation and are associated with resistance to endocrine therapy. For example, HER2 overexpression results in ERa phosphorylation and resistance to tamoxifen treatment in vitro (Shou et al., 2004; Pancholi et al., 2008) and it is associated with resistance to endocrine therapy in vivo (Benz et al., 1992; Yamashita et al., 2008; Kok et al., 2009) . In spite of this the molecular mechanisms governing resistance to endocrine therapy remains largely unclear.
Previously, along with others, we have shown that a subset of ERa-positive breast cancers express high levels of mRNA transcripts encoding RET (REarranged during Transfection) and its co-receptor GFRA1 (GDNF receptor family a1) and that RET signaling in ERa-positive breast cancer cell lines can result in the activation of the mitogen-activated protein kinaseextracellular signal-regulated kinase (ERK)1/2 and AKT pathways (Esseghir et al., 2007; Boulay et al., 2008) . As activation of these pathways has been shown to be associated with ERa signaling and response to endocrine therapy (Gee et al., 2001; Nicholson et al., 2001; Perez-Tenorio and Stal, 2002; Osborne et al., 2005) , the aims of this study were to investigate whether RET signaling in ERa-positive breast cancers: (i) effects on ERa phosphorylation and transcriptional activity, (ii) modulates the sensitivity to tamoxifen treatment and (iii) has a role in determining tamoxifen resistance.
Results
GDNF-mediated RET signaling in ERa-positive breast cancer cells A key event in estrogen-independent activation of ERa is phosphorylation of serine residues within the AF1 domain by upstream kinases. To analyze a potential cross-talk between RET and ERa signaling, ERapositive and RET-positive estrogen-deprived MCF7 cells were serum-starved overnight and treated with the RET ligand GDNF (Figure 1a ). GDNF stimulation resulted in phosphorylation of RET and triggered a fast and sustained activation of the ERK1/2 and AKT pathways but a more transient activation of c-Jun-NH2-kinase (JNK), as previously reported (Esseghir et al., 2007; Boulay et al., 2008) . In this study, we show that GDNF treatment resulted in a sustained increase in mTOR (Ser2481) and p70S6K (Thr389) phosphorylation and transient activation of p38. Moreover, examination of the phosphorylation status of ERa revealed a fast and transient increase in Ser118 ERa phosphorylation but a more sustained phosphorylation at Ser167. Phosphorylation of ERa at Ser104/106 was not observed. Ser104/106 is a substrate for cyclin A-CDK2 complex (Rogatsky et al., 1999) , indicating that this complex is not activated downstream of RET signaling in breast cancer cells. To support these findings, cells were analyzed in parallel by confocal microscopy ( Figure 1b) . Again, a rapid and transient increase in ERa Ser118 phosphorylation was observed after GDNF stimulation.
To confirm that RET is required for the GDNFinduced ERa phosphorylation, MCF7 cells were treated with control or RET small interfering RNA (siRNA) oligonucleotides (see Figure 4 for siRNA oligonucleotide characterization). GDNF-induced signaling as monitored by western blotting (Figure 2a ) and confocal microscopy ( Figure 2b ) was unaffected by transfection with control siRNA but abrogated by siRNA-mediated downregulation of RET expression. Interestingly, it was noted that ERa levels decreased in GDNF-stimulated RET siRNA-treated cells. This observation would suggest a role for GDNF/RET signaling in the maintenance and stability of ERa. A potential mechanism by which this might occur is through inhibiting ERa degradation in the ubiquitin-26S proteasome system (Berry et al., 2008) . These data show, for the first time, the existence of a functional pathway that connects RET signaling with ERa Ser118 and Ser167 phosphorylation in breast cancer cells.
RET signaling promotes estrogen-independent ERa transcription
To analyze the functional consequence of RET-induced ERa phosphorylation, the transcription of ERa-dependent genes induced by GDNF was examined in estrogen-deprived MCF7 cells that had been treated overnight with or without ICI182780 (fulvestrant). ICI182780 is a potent ERa inhibitor that induces ERa degradation and thereby allows discrimination between genes that are regulated by ERa-dependent and -independent mechanisms. GDNF treatment induced the upregulation of two known ERa target genes CCDN1 and FOS (Frasor et al., 2003) and, importantly, this upregulation was blocked by pretreatment with ICI182780 ( Figure 2c ). In contrast, upregulation of EGR1, a known RET transcriptional target that is not associated with ERa-mediated transcription, was unaffected by ICI182780 treatment. These data show that GDNF can signal through RET to mediate estrogenindependent activation of ERa transcriptional activity.
mTOR is a key component in GDNF-RET-induced ERa phosphorylation To delineate the cascade that connects RET signaling with Ser118 and Ser167 ERa phosphorylation, cells were treated with inhibitors targeting the main effector pathways activated by GDNF (Figure 3a ). Of these, only the mTOR inhibitor rapamycin completely blocked, at nanomolar concentrations, the GDNFinduced ERa phosphorylation at Ser118 and Ser167. This effect was also observed by immunostaining cultured cells with a phospho-specific ERa Ser118 antibody ( Figure 3b ). No significant effect on ERa phosphorylation was observed with the JNKII, p38 or MEK1/2 inhibitors. A small but reproducible inhibition of Ser118 but not Ser167 phosphorylation was associated with the phosphatidylinositol 3 kinase inhibitor wortmannin (Figures 3a and b) . This result indicates that in this system activation of mTOR downstream of RET is not solely dependent on AKT. In this respect, it was noted that although the MEK1/2 inhibitor had only a minor effect on ERa phosphorylation, it increased the level of AKT phosphorylation. This raises the possibility that there is a functional interaction between AKT and MEK1/2-ERK1/2 providing a compensatory mechanism of these two pathways in breast cancer cells.
Targeting RET sensitizes breast cancer cells to 4-OH-tamoxifen To date, no studies have investigated a role for RET in modulating the response to endocrine therapy. In this study, we examined first the effects of GDNF treatment on the response of MCF7 cells to the selective ER modulator 4-OH-tamoxifen. As expected, treatment with 4-OH-tamoxifen resulted in a significant decrease in colony formation when MCF7 cells were plated onto a bed of Matrigel (Figure 4a ). GDNF treatment promoted MCF7 cell colony formation and, consistent with our data showing that GDNF stimulated an increase in ERa phosphorylation and transcriptional activity (Figures 1 and 2 ), protected the cells against 4-OH-tamoxifen treatment. Next, we analyzed the effects of targeting RET on the response to 4-OH-tamoxifen.
Of the different RET siRNAs tested; maximal downregulation of mRNA and protein levels was achieved with the RET Smartpool siRNA (siRETsp) and individual siRNA oligonucleotides siRET5 and siRET6 ( Figure 4c ). Dose-response survival curves performed over a range of 4-OH-tamoxifen concentrations from 10 À9 to 10 À6 M showed that RET silencing resulted in a significant increase in the sensitivity of MCF7 cells to 4-OH-tamoxifen when compared with siRNA controltransfected cells (Figure 4c ). For example, the SF50 in siRET5-transfected cells was 8.3±3.4 nM compared with 51.88 ± 1.98 nM for siRNA control-transfected cells (Po0.001) resulting in a 6.2-fold increase in sensitivity to 4-OH-tamoxifen. 
RET expression in breast cancers
Using an in situ hybridization screen of invasive breast cancers arrayed in a tissue microarray (TMA), we reported previously high RET mRNA levels in 29.7% of cases and a significant correlation with ERa expression (Esseghir et al., 2007) . Consistent with these data, in silico analysis from four independent microarray studies using the Oncomine database showed a significantly higher level of RET transcripts in ERapositive compared with ERa-negative tumors (Supplementary Figure 1) . In this study, we first confirmed that the increased levels of RET transcripts in these tumors corresponded to increased expression of RET protein. A RET antibody was optimized to give robust immunohistochemical staining of formalin-fixed (b) Cells were fixed, permeabilized and immunostained with RET and phospho-specific Ser118 ERa antibodies followed by Alexa488 anti-rabbit Ig (green) and Alexa555 anti-mouse Ig (red) secondary antibodies, respectively. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale, 37.5 mm. Figure 2) and then used to stain the same TMA of invasive breast cancers (Figure 6a ). In agreement with the in situ hybridization data (Esseghir et al., 2007) , RET protein expression was detected in 25.5% (41 out of 161) of cases in which it was observed in the tumor cells and excluded from the surrounding stroma. Again, this expression significantly correlated with a positive ERa status (P ¼ 0.047). Moreover, within the ERa tumors, RET expression significantly correlated with a higher level of ERa expression as shown by a higher median histo-score (H-score) (P ¼ 0.0187). Next, following the same protocol, we stained an independent TMA of primary breast cancers from patients who had received adjuvant tamoxifen treatment and subsequently developed recurrent disease (Figure 6b ). RET expression was detected in 56.1% (37 out of 66) of total cases and 59.6% (31 out of 52) of ERa-positive cases. This represents a significantly higher percentage of RETpositive tumors than in the non-selected invasive breast cancer TMA (Figure 6a ) whether comparing all tumors (2.2-fold increase, Po0.0001) or only ERa-positive tumors (2.0-fold increase, P ¼ 0.0003). Finally, within the ERa-positive tumor samples, RET expression showed a strong trend with higher median ERa H-score (P ¼ 0.055) (Figure 6b ).
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Discussion
Resistance to endocrine therapy has been the subject of intense study over recent years. Current data suggest that during the development of resistance there is a shift in the phenotype of the breast cancer cells from growth dependence on steroid hormone receptors toward nonsteroidal growth factor-dependent pathways (Arpino et al., 2008) . During this process, the cells may become hypersensitive to estrogen as a result of estrogen-independent Parallel cultures on glass coverslips were fixed, permeabilized and immunostained with RET and phospho-specific Ser118 ERa antibodies followed by incubation with Alexa-488 antirabbit Ig (green) and Alexa-555 anti-mouse Ig (red) secondary antibodies, respectively. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale, 37.5 mm. (c) Estrogen-deprived MCF7 cells were serum-starved overnight in the presence or absence of 1 mM ICI182780. The following day, cells were stimulated with GDNF (20 ng/ml) for 0, 30 or 120 min. Quantitative PCR analysis was performed for the genes FOS, EGR1 and CCNDI. Data were normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and represent the mean ± s.e.m., n ¼ 3 (CCND1, EGR1), n ¼ 2 (FOS). *Po0.05, **Po0.01.
phosphorylation of ERa and/or associated co-activators (Kurokawa et al., 2000; Shim et al., 2000; Yue et al., 2002; Martin et al., 2003; Shou et al., 2004) or independent of steroid receptors that are downregulated as a result of aberrant intracellular signaling (Oh et al., 2001; Creighton et al., 2006; Massarweh et al., 2008; Pancholi et al., 2008; Sabnis et al., 2008) . Although a number of clinical studies support these observations (Gutierrez et al., 2005; Dowsett et al., 2006; Arpino et al., 2007 ) the molecular mechanisms underlying these phenotypes remain unclear and as a consequence, effective approaches for preventing and overcoming resistance are not yet available (Johnston, 2009) .
In this study, we show for the first time, the existence of a functional pathway that connects GDNF/RET signaling with phosphorylation of ERa at Ser118 and Ser167. Further, the observation that GDNF treatment results in estrogen-independent transcriptional upregulation of ERa response genes FOS and CCND1, and that this upregulation can be blocked by pretreatment with the ERa inhibitor ICI182780 (fulvestrant) shows the existence of a GDNF/RET-dependent estrogenindependent ERa activation pathway. Further interrogation of this pathway revealed that neither inhibition of ERK1/2 or AKT alone had a major effect on phosphorylation of ERa Ser118 or Ser167. This is consistent with previous reports showing that MCF7 cells have a high degree of plasticity with the ability to switch between these pathways to phosphorylate ERa (Kato et al., 1995; Joel et al., 1998a Joel et al., , 1998b Campbell et al., 2001 ). In contrast, our studies identified a prominent role for the mTOR/p70S6K pathway in activation of the ERa as inhibition with rapamycin abrogated phosphorylation of ERa Ser118 and Ser167. Although previous studies have also shown an extensive cross-talk between ERK1/2 and mTOR and that their downstream effectors, p90RSK and S6K1 converge on common targets, in particular those controlling protein translation (Shahbazian et al., 2006; Roux et al., 2007; Abe et al., 2009) , recent reports have shown that that mTOR/S6K1 and ERK1/2/p90RSK contribute nonoverlapping inputs into ERa activation through Ser167 phosphorylation (Yamnik et al., 2009) . Taken together these observations provide insight into previous studies that have reported additive/synergistic effects of rapamycin and tamoxifen on MCF7 cell survival in vitro (Chang et al., 2007; Ghayad et al., 2008) and that in tamoxifen-resistant cell lines, co-treatment with rapamycin in vitro or the ester of rapamycin CCI-779 in vivo inhibited mTOR activity and restored tamoxifen sensitivity (deGraffenried et al., 2004) . However, in the clinical trials in breast cancer patients evaluating the efficacy of mTOR inhibitors alone or in combination with endocrine therapy, the response among patients has been variable (Johnston, 2009 ). This may reflect the lack of biomarkers available to identify those patients who are most likely to respond to this treatment. In this study, we show that siRNA-mediated downregulation of RET expression in MCF7 cells resulted in a 6.2-fold enhancement in sensitivity to the antiproliferative effects of 4-OH-tamoxifen, whereas GDNF treatment had a protective effect against the drug. From a clinical perspective this suggests that in RET-positive/ERapositive tumors, the combination of tamoxifen with a RET or mTOR inhibitor as adjuvant therapy may prove more beneficial that tamoxifen alone.
As the pathways activated by RET in breast cancer cells have been implicated in resistance to endocrine therapy, we also assessed the effect of targeting RET in a MCF7 cell line that models resistance to tamoxifen (TAM R -1 cells). Downregulation of RET re-sensitized TAM R -1 cells to the anti-proliferative effects of 4-OHtamoxifen. Interestingly, TAM R -1 cells also show elevated level of phosphorylated ErbB2 and the magnitude of re-sensitization to tamoxifen in the RET siRNA-treated cells was equivalent to that previously reported for the ErbB2 inhibitors AG825 and lapatanib (Pancholi et al., 2008; Leary et al., 2010) . Consequently, these data presented here provide evidence that RET is Figure 3 RET signaling induces ERa Ser118 and Ser167 phosphorylation through mTOR. Estrogen-deprived MCF7 cells were serum-starved overnight and either untreated (À) or treated with the following kinase inhibitors UO126 (2 mM), wortmannin (1 mM), p38 inhibitor (2 mM), the JNKII inhibitor (2 mM) and rapamycin (500 nM) for 2 h followed by GDNF stimulation (40 ng/ml, 15 min). (a) Total cell protein extracts were subject to western blotting analysis using the indicated antibodies. Blots shown are representative of data obtained in three independent experiments. (b) In parallel, cell cultured on glass coverslips were fixed, permeabilized and stained with RET and phospho-specific Ser118 ERa antibodies followed by Alexa488 anti-rabbit Ig (green) and Alexa555 anti-mouse Ig (red) secondary antibodies, respectively. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale, 37.5 mm.
an important mediator in the TAM R -1 phenotype. These data also raise the possibility that the higher SF50 for tamoxifen-treated TAM R -1 cells compared with MCF7 cells could result from a higher plasticity in the TAM R -1 cells that allows them to use either RET or ErbB2 signaling depending on the pressures placed on them.
Using an in situ hybridization screen of invasive breast cancers arrayed in a TMA, we reported previously a significant correlation of RET mRNA levels with ERa expression (Esseghir et al., 2007) . In this study, we have implemented a robust protocol for RET immunohistochemical staining and corroborated that the increased levels of RET mRNA in ERa-positive breast cancers corresponded to increased levels of RET protein. Using this protocol, we examined RET protein expression in primary breast cancers from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment to validate its clinical significance. Strikingly, there was a twofold increase in the number of RET-positive tumors compared with the non-selected breast cancers. This increased RET expression, together with the TAM R -1 in vitro studies, reveals a new role of RET in mediating tamoxifen resistance. Finally, it was notable in these studies that RET expression in both tumor sets examined correlated with a higher median ERa H-score. The RET gene contains an estrogen response element (Lin et al., 2007) and estrogen stimulation of MCF7 cells results in increased levels of RET protein (Boulay et al., 2008) . Together, the implications for these data are threefold. First, they show that RET expression in ERa-positive primary tumors may result, at least in part, from a RET-ERa autocrine loop. Second, that RET expression may be a useful criteria to subset patients who will respond to inhibitors of mTOR such as rapamycin. Third, they identify RET as a potential therapeutic target to enhance sensitivity of breast cancers to endocrine therapy and/or to re-sensitize tumors that have developed endocrine-resistance.
Materials and methods
Cell culture media and reagents MCF7 cells were maintained long-term in RPMI 1640 medium without phenol red supplemented with 10% dextran charcoaltreated fetal bovine serum (HyClone, South Logan, UT, USA), 1 nM 17-b estradiol (Sigma, Dorset, UK), 2 mM L-glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin. For estrogen deprivation, cells were cultured for 3 to 4 days RET expression is shown relative to expression in siRNA control (siCON)-transfected cells. Data represent mean ± s.e.m., n ¼ 3. RET protein expression levels were assessed by Western blotting. Data shown are representative of two independent experiments. (c) MCF7 cells were transfected with the indicated siRNA oligonucleotides. After 24 h, cells were split into 4-6 wells and exposed continuously to the indicated concentrations of 4-OH-tamoxifen or vehicle for 7 days. Cell number was measured using the CellTiter-Glo assay. Data represent mean survival fraction ± s.e.m., n ¼ 6 (siRET5, siRET6), n ¼ 2 (siRETsp)., ***Po0.001.
with RPMI media in the absence of 17-b estradiol. Tamoxifenresistant (TAM R -1) MCF7 cells were grown in Dulbecco's modified Eagle's medium/F12 medium without phenol red supplemented with 1% fetal bovine serum and 10 À6 M tamoxifen (Sigma). Stock solutions were as follows: 4-OH-tamoxifen: 10 mM in ethanol; 17-b estradiol, 1 mM in ethanol; ICI182780 (faslodex or fulvestrant, Tocris Bioscience, Bristol, UK) 10 mM in dimethylsulphoxide; MEK1/2 inhibitor U0126, rapamycin and wortmannin (Cell Signaling, New England Biolabs, Hitchin, Herts, UK), p38 and JNKII inhibitor (Calbiochem, San Diego, CA, USA); 20, 10, 2, 2 and 20 mM, respectively, in dimethylsulphoxide.
Antibodies
The following antibodies: RET (C31B4), mTOR, phosphoSer2448 mTOR, p70S6K, phospho-Ser389 p70S6K, JNK, phospho-Thr183/Tyr185 JNK, p38, phospho-Thr180/ Tyr182 p38, ERa (62A3 for use in western blotting), phospho-Ser104/106, -Ser118 (16J4), Ser167 ERa were purchased from Cell Signaling (New England Biolabs). Anti-ERa antibody 6F11 for use in immunohistochemistry was purchased from Vector Laboratories (Peterborough, UK). All the others antibodies have been described elsewhere (PlazaMenacho et al., 2005 (PlazaMenacho et al., , 2007b . Protein lysates and western blotting analysis were performed as described previously (Plaza-Menacho et al., 2007b) .
siRNA oligonucleotides
The following siRNA oligonucleotides RET SMARTpool, siControl SMARTpool, RET5, RET6, RET7, RET8 were purchased from Dharmacon (Empson, UK). For transfection of siRNAs, 100 nM of the indicated siRNA oligonucleotides was combined with Dharmafect transfection reagent 3 according to the manufacturer's instructions.
Quantitative real-time PCR RNA extraction, complementary DNA synthesis, quantitative RT-PCR reaction and gene expression analysis were performed as previously described (Esseghir et al., 2007; PlazaMenacho et al., 2007a) . The Assays-on-Demand references are as follow: RET Hs00240887_m1, EGR1 Hs00152928_m1, FOS Hs00170630_m1, CCND1 Hs00277039_m1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (control) 4310884E.
Tamoxifen response assays
Unless otherwise stated, tamoxifen response experiments were performed as described previously (Iorns et al., 2008) . Briefly, 3500 cells per well were plated in 96-well plates and transfected with 100 nM siRNA oligonucleotides. The following day cells were split into four to six replicate wells and cultured in media with ethanol vehicle or 10 À10 to 10 À6 M 4-OH-tamoxifen. Media/ drug mixes were replaced every 48 h. Survival fraction after 7 days was measured using CellTiter-Glo luminescent cell viability assay according to the manufacturer's instructions (Promega, Madison, WI, USA) using a Victor 2 V Multilabel HTS counter (Wallac-Perkin Elmer, Herts, UK). For three-dimensional culture, 0.2 ml of growth factor reduced and phenol red free Matrigel (BD Biosciences, Oxford, UK) diluted 1:1 in phosphate-buffered saline per well was plated into 24-well tissue culture dishes and left at 37 1C for 2-3 h. Next, 10 000 cells were single cell-seeded per well and cultured overnight. The following day, cells were stimulated with GDNF (50 ng/ml, BD Biosciences) and treated with 4-OH-tamoxifen (10 À7 M) or vehicle (ethanol) as indicated. Medium was replaced every 3 days and colonies larger than 100 mm were counted at 10 days.
TMA and immunostaining
Studies using human breast cancer samples were approved by the research ethics committee of the Royal Marsden NHS Foundation Trust. The invasive breast cancer TMA contained duplicate 0.6 mm cores of 245 carcinomas. All patients were primarily treated with surgery, followed by anthracyclinebased chemotherapy and endocrine therapy for patients with ER-positive tumors. Full details of the TMA characterization and the cohort of patients are described elsewhere (Reis-Filho et al., 2006; Esseghir et al., 2007; Savage et al., 2007) . The second TMA contains cores from the primary tumors of 77 patients diagnosed between 1981 and 2004 at the Royal Marsden Hospital who developed subsequent invasive recurrence after adjuvant tamoxifen treatment. This included 51 patients included in an earlier report (Gutierrez et al., 2005) . For RET immunohistochemistry, antigen retrieval was 2 min in a pressure cook with the Dako (Ely, Cambridgeshire, UK) target retrieval solution followed by anti-RET antibody applied at 1/100 dilution and detection was with the Vectastain avidin-biotin complex system used according to the manufacturer's instructions (Vector Laboratories). For ERa immunohistochemistry, antigen retrieval was by microwave for 5 min at full power (900 W) in citrate buffer pH 6.0. Antibody (6F11) was applied at 1/40 dilution. Nuclear ERa was scored using the H-score and classed as positive if H-score41.
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad Software, La Jolla, CA, USA). Survival assays and quantitative PCR were compared using two-way ANOVA and the Bonferroni or Dunnet test. For the correlation of the tumor staining, contingency tables and column analysis were analyzed using the Pearson 0 s chi-square, the Fisher's exact test or the Mann-Whitney test, as indicated. Differences were considered statistically significant when Po0.05. 
